Gjertsen is Director at KG Jebsen Centre of Myeloid Blood Cancer. He served as co-Director for Centre for Cancer Biomarkers (CCBIO) Norwegian Centre of Excellence, University of Bergen, 2016–2022. In 2010-2018, he developed the phase I clinical trials unit at Haukeland University Hospital. His clinical practice is focused on clinical trials in CML and AML, and several early phase clinical trials in AML has been established with single cell biomarker programs for disease profiling and response evaluation. His laboratory is working on intracellular signal transduction, single cell analysis and immune cell profiling for early response evaluation. In 2024 Gjertsen was awarded a five-year KG Jebsen Centre for Myeloid Blood Cancer, focused on signalling targeted therapy guided by single cell signalling profiles tumor and immune cells. Funding support: Norwegian Cancer Society, the Helse Vest Health Trust, the Research Council of Norway, EU TRANSCAN-3 and ERA PerMed. Dr. Gjertsen is founding member and chair of the Norwegian AML Group and the Nordic AML Group, and is member of the Nordic CML Study Group.